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Summary XR9051 (N-(4-(2-(6,7-Dimethoxy-1.2,3,4,-tetrahydro-2-isoquinolyl)ethyl)phenyl)-3-((3Z,6Z)-6-benzylidene-1 -methyl-2.5-dioxo-3-
piperazinylidene) methylbenzamide) was identified as a potent modulator of P-gtycoprotein-mediated multidrug resistance (MDR) following a
synthetic chemistry programme based on a natural product lead compound. The actvity of XR9051 was determined using a panel of human
and murne drug-resistant cell lines (H69/LX4, 2780AD, EMT6/AR 1.0, MC26 and P388/DX Johnson). XR9051 was able to reverse resistance
to a variety of cytotoxic drugs, including doxorubicin, etoposide and vincristine, which are associated with classical MDR. At a concentration of
0.3-0.5giM, XR9051 was able to fully sensitize resistant cells to cytotoxics, whereas little or no effect was observed on the corresponding
parental cell lines. No effect of XR9051 was observed on the response of cells to non-MDR cytotoxics such as methotrexate and 5-fluorouracil.
XR9051 was consistently more potent than cyclosporin A (CsA) and verapamil (Vpm) in all assays used. XR9051 inhibited the efflux of
[3H]daunorubicin from preloaded cells and, unlike CsA and Vpm, remained active for several hours after removal of resistance-modifying agent.
In photoaffinity labelling experiments employing [3H]azidopine, XR9051 was able to displace binding to P-glycoprotein. In binding studies using
[3H]vinblastine, XR9051 was shown to be a potent inhibitor ofthe binding ofthe cytotoxic to P-glycoprotein (ECO= 1.4 ± 0.5 nM). Taken together.
the results indicate that XR9051 reverses the MDR phenotype through direct interaction with P-glycoprotein.
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The treatment ofcancer with chemotherapeutic drugs is frequently
impaired or ineffectixe as a result of intrinsic or acquired resis-
tance of the tumour cells. Many types of cancer. such as solid
tumours of the colon and lix-er. appear innatelv refractorv to the
cvtotoxic influence of anti-cancer drucs. wNhereas others. such as
breast and oxarian cancers. often respond w-ell initially but subse-
quently relapse. Multidrug resistance (MDR) is the phenomenon
in which exposure of tumour cells to a single cytotoxic agent
results in cross-resistance to other structurallx unrelated classes of
cxtotoxics (Gottesman and Pastan. 1993). This familx of 'MDR
cytotoxics includes drugs of clinical importance such as the
anthracvclines. Xinca alkaloids and paclitaxel (Gottesman and
Pastan 1993).
Althouah there are sexeral different mechanisms bx which
resistance can emerge (Simon and Schindler. 1994) by far the most
extensixvelv characterized is P-glycoprotein-mediated MDR. P-
glxcoprotein (P-gp) is a plasma membrane protein of 170 kDa that
is encoded bv the MDR] gene and acts as an energNx-dependent
drug efflux pump. preventing the accumulation of drugs by
expelling them from the cell membrane before they are able to
interact w-ith their cellular target (Gottesman and Pastan. 1993).
The clinical sianificance of P-ggp in haematological malignancies
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has been well documented. but at present its role in solid tumours
is less clear.
A broad range ofcompounds has been identified that are able to
rexverse the MDR phenotype by interacting with P-gp and blocking
the efflux of cvtotoxics from cells. These compounds include
peptides. steroids. calcium channel blockers. cardiox ascular drugys
and immunosuppressix e and antifungal agents (reviewed by Ford.
1996). Their use has been limited bx the inabilitN to achiexe clini-
cally effectixe plasma or tumour concentrations to inhibit P-gp
function before non-specific. deleterious toxicities are encoun-
tered (Lum et al. 1993: Raderer and Scheithaeur. 1993). The
requirement for more selectixe and potent agents as resistance
modifiers has led to the identification of a number of second-
generation modulators. such as a non-immunosuppressix e
cxclosporin derivatixe SDZ PSC 833 (Boesch et al. 1991). an
acridonecarboxamide derixatixe. GG918 (Hvafil et al. 1993). and
a triazinoaminopiperidine derixitixe. S9788 (Pierre et al. 19921.
These compounds are currentlx in clinical trial. The demonstration
that potent modulators can oxercome resistance in P-gp-oxer-
expressing cell lines and tumours is a vital step in answerinc the
question ofwhether inhibition ofP-gp function will be an effectix e
therapeutic strategy.
XR9051 (Figure 1) xas identified from a medicinal chemistrx
programme based on a diketopiperazine originally isolated from
the fermentation of a Streptomyces species. In this paper. we
descnrbe the in X itro profile of XR905 1. wxhich illustrates its
promise as a nexx drug for the treatment ofMDR tumours.
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Figure 1 Structure of XR9051
MATERIALS AND METHODS
Cell lines
Parental EMT6 mouse mammary carcinoma (EMT6/P) and H69/P
small-cell lung carcinoma cell lines and their corresponding
drug-resistant sublines EMT6/AR 1.0 (Twentyman et al. 1990)
and H69/LX4 (Twentyman et al. 1986) were from stocks held
by the MRC Clinical Oncology and Therapeutics Unit.
Cambridge. UK.
Parental A2780 human ovarian carcinoma cells and their drug-
resistant counterparts 2780AD (Rogan et al. 1984) were provided
by Dr T Hamilton (Fox Chase Cancer Center. Philadelphia. PA.
USA).
Parental murine P388 leukaemia (P388/P) and drug-resistant
P388/DX Johnson cell lines (Johnson et al. 1978) were kindly
provided by Dr M Grandi (Pharmacia Upjohn. Milan, Italy).
The MC26 murine colon carcinoma cell line, which is intrinsi-
cally drug resistant. at least in part as a result of P-gp expression.
was provided by Dr SA Watson (University Hospital. Nottinghamn
UK).
All cell lines were maintained in RPMI-1640 medium (Gibco)
supplemented with L-glutamine (2 mm) and 10% fetal calf serum
at 37°C in a humidified atmosphere of 95% air and 5% carbon
dioxide. P388/P and P388/DX Johnson cultures were additionally
supplemented with 6 miM 2-mercaptoethanol. All drug-resistant
lines, with the exception ofCHrB30 cells, were maintained under
positive selection pressure by treatment with doxorubicin for one
passage every 3-4 weeks. These doxorubicin-treated cultures were
subsequently incubated in drug-free medium for one passage
before experimental use. The drug-resistant Chinese hamster
ovary cell line CHrB30 was grown in a-MEM supplemented with
nucleosides and 30 jg ml-' colchicine to maintain resistance as
described previously (Kartner et al, 1983). The same medium but
lacking colchicine was used to culture the parental AuxB1 cell
line.
Drugs
Cytotoxic drugs doxorubucin. vinblastine. vincristine. etoposide.
colchicine. methotrexate. actinomycin D, 5-fluorouracil (all
Sigma) and paclitaxel (Calbiochem) were prepared as 10-20 mu
stock solutions in DMSO, with the exception of doxorubicin.
which was dissolved in sterile distilled water to a concentration of
500gg ml-'. XR9051 (free base, chlorhydrate or mesylate salt)
was prepared by chemical synthesis at Xenova and was dissolved
in DMSO to give a stock concentration of5 mm. Resistance-modi-
fying agents (RMAs) verapamil (Vpm; Sigma) and cyclosporin A
(CsA; Calbiochem) were dissolved in ethanol to give stock
concentrations of 10 mm. Aliquots of drugs were stored at -200C
and diluted as appropriate in culture medium before use.
Drug potentiation assays
Cells were tiypsinized from monolayers and diluted to a density of
8 x 10 to 6 x 10 cells ml-'. depending on the cell line. Aliquots of
100 p1 were pipetted into wells of 96-well tissue culture plates
(Falcon) and cells allowed to adhere for 4 h. Modulators dissolved
in culture medium at fourfold concentration or appropriate solvent
controls were then added in a volume of50 p1 per well at a range of
concentrations. each dose being tested in four replicate wells. After
a further 1-h incubation. cytotoxics were added at fourfold concen-
tration in a volume of 50 gl. Plates were then incubated for 4 days
(EMT61P. EMT6/AR 1.0 and MC26) or5-6 days (A2780. 2780AD)
before cell proliferation was assessed using the sulphorhdiamine B
(SRB) assay as described previously (Skehan et al. 1990).
For suspension cultures cellular proliferation was quantified
after the appropriate incubation period (5-6 days for H69/P:
H69/LX4; 4 days for P388/P:P388/DX Johnson) using the redox
reagent AlamarBlue (Serotec. UK). At the end of the incubation
period. 20 g1 of AlamarBlue was added to each well and plates
returned to the incubator for 5-8 h to allow colour development.
Absorbance was subsequently read using a CL320 Microplate
Reader (Bio-Tek Instruments) at a wavelength of 570 nm. refer-
ence wavelength 600 nm.
Accumulation of pH]daunorubicin in EMT6/P and
EMT61AR 1.0 cells
Cells (9.6 x I0 EMT6/AR 1.0: 4 x I0 EMT6/P) were seeded into
white 96-well culture plates (Canberra Packard) in medium and
cultured for 48 h. To commence experiments. the medium was
removed and replaced with 250 g1 of culture medium buffered
with 50nrmu Hepes. pH7.4. containing a total daunorubicin
concentration of 2 jM including 0.3 jCi ml-' [ Hldaunorubicin
(stock approximately 1.4 Ci mmol-'. NEN) and modifying agent
when appropriate. After incubation for 1 h at 37°C, plates were
rapidly washed four times with ice-cold phosphate buffered saline
(PBS) and allowed to air-dry. Microscint 40 scintillant (200gil:
Canberra Packard) was added. plates sealed and cell-associated
radioactivity detenrnined using a TopCount scintillation counter
(Canberra Packard).
Effiux of PHcdaunorubicin from EMT6/AR 1.0 cells
This assay was carried out according to Hyafil et al (1993).
Briefly. cells were seeded at a density of4.8 x 10 per well in 24-
well plates (Falcon). After allowing cells to proliferate for 48 h.
culture medium was removed and replaced with 0.5 ml of loading
medium (glucose-free culture medium supplemented with 10 mm
sodium azide. 50 nm. Hepes. pH 7.4.2 jm daunorubicin including
0.3 jCi ml-' [H]daunorubicin and resistance-modifying agents, as
appropriate). Plates were incubated at 37°C for 2 h before washing
wells rapidly twice with growth medium and replacing with
.efflux medium' (culture medium supplemented with 50 mM
Hepes, pH 7.4, with or without resistance-modifying agent) and
further incubation at 37°C. At varying time points during the
efflux phase, wells were washed rapidly four times using ice-cold
PBS and left to dry. At the end ofthe assay. cells were solubilized
in 500 jil 0.1 N sodium hydroxide and transferred to scintillation
vials containing 4.5 ml of scintillation fluid. Cell-associated
radioactivity was measured using a Canberra Packard TriCarb
2000 scintillation counter.
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Table 1 Sensitization of MDR cell lines to doxorubicin by XR9051. verapamil and cyckosporin A
IC., doxorubicin (jiu)
Drug-sensitive cells H69/P A2780 EMT6/P
No modulator 0.0143 0.022 0.009
1.0 gM XR9051 0.0123 0.018 0.003
Drug-resistant cells H69A(4 2780D EMIT6/AR1.0 MC26
No modulator 0.705 0.745 0.751 0.031
XR9051 0.1 UM 0236 0.536 0.134 0.019
0.3 UM 0.047 0.038 0.011 0.007
0.5 gM 0.040 0.028 0.008 0.005
1.0 gM 0.035 0.018 0.004 NDr
CsA 0.1 iM 0.745 0.622 0.532 0.018
0.3 gM 0.480 0.566 0.071 0.009
0.5 gM 0.330 0.248 0.026 0.005
10 UM 0.108 0.065a 0.009a ND
Verapamil 0.5 gM 0.230 0.221 0.113 0.014
1.O M 0 132 0.144 0.044 ND
3.0 gM 0.048 0.058 0.014 ND
5.0 uM 0.036 0.045a 0.009a ND
Each value represents the result of a single experirnent, performed in quadruplicate wells, and is representative of at least
three separate experiments. aToxic: modulator alone inhibited cell growth by greater Fan 20%O of control value. nND. not done.
Persistence of activity after removal of modulator
EMT6/ARl.O cells (9.6 x 101 per well) were seeded into 96-ssell
culture plates (Canberra-Packard) and allowed to attach for 48 h.
Cells were then incubated % ith modulators for 1 h before washing
with w-arm culture medium and further incubation at 37 C in
normal medium. At subsequent time points after remosval of
modulator as indicated. the abilitv of the cells to accumulate
[ H]daunorubicin sas assessed using the assay detailed in the
previous section.
Photoaffinity labelling of P-gp
CeHl membranes from H69/P and H69/LX4 cells were prepared for
use mphotoaffinity labellinc assays as described presviously (Barrand
et al. 1992). For labeHfing studies 50get of membranes in 10jl of
1 nv\t Tris. pH7.4. was incubated in the dark with concentrations of
modulatinc agents and 0.03 jm\ [LH]azidopine (49 Ci mmol-'.
Amersham) for 1 h at ambient temperature. Samples were then
exposed to LTV light for 30 min before solubilization in Laemmli
buffer. Samples were not boiled because ofdescribed aggregation of
P-gp at high temperature in sample buffer (Greenberger et al. 1988).
After separation of proteins on a 7.5%C polyacnlamide rel. the gel
was fixed, amplified for autoradiography using, Amplifx (Amersham
Intemational. UK). dried and exposed to photosensitive film for
approximately 1 week at -70^C.
Equilibrium binding of [H]vinblastine by CHrB3E
plasma membranes
Plasma membranes were isolated from CHrB30 and AuxB1 cells
accordinc to previously published methods (Lever. 1977). Cells
sere disrupted by nitrogen casitation ( 1500 psi) and membranes
purified by sucrose density centrifuration. Purified membranes
w-ere stored in 10 mms Tris-hydrochloric acid pH 7.4. 0.25 m
sucrose at -70CC for up to 6 months w-ithout loss ofactivity.
A rapid filtration assay was used to determine the equilibrium
bindinc of [ Hjvinblastine to CHrB30 membranes as previously
described (Ferrv et al. 1992). Briefli- membranes (20 go) and
['H]isinblastine (25-30 nm) were incubated in the absence and
presence of competing drug (10-"' to I0- mi) in binding buffer
(0.05 mi Tris-hydrogen chloride. pH 7.4) at room temperature in
the dark for 120 mIii. Following the appropriate incubation period.
3 ml of wash buffer (0.02 mi maanesium chloride. 0.05 mi Tris-
hydrochloric acid. pH 7.4) was added and the samples vacuum
filtered through two GF/F membranes in a Millipore Filtration
Manifold. Filter-retained radioactisvits %vas measured by liquid
scintillation countin. Non-specific binding (usually about 10%N
total) was defined as the amount of ['H]vinblastine bound in the
presence of 3 gi unlabelled svinblastine and w-as subtracted from
all values. There s-as no specific bindinc of ['H]svinblastine to
plasma membranes from the non-P-gap-expressing AuxB1 cell line
(data not show-n).
Displacement of sinblastine bindinc by the ligands (10-l0' to
I0- i) was performed in a total assay solume of 1 ml. Stock solu-
tions ofcompeting compounds were made in DMSO and added to
the samples as a 2 jl aliquot. gis ing a final DMSO concentration
of 0.2%c DMSO (s/s-). This solsent can displace ['H]sinblastine
binding with an ICNl salue of 2.5% (s/s).
Results for each compound wsere expressed as a fraction of the
total specific binding of ['H]isinblastine in the absence of
competing drug. The potencies ofdrugs to displace ['H]svinblastine
binding to P-ggp swas assessed by non-linear regression using the
general dose-response equation (DeLean et al. 1978): Y =
[a -b)/( 1 + (XIc)d)] + b. where Y= fraction bound. a = initial frac-
tion bound. b = final fraction bound. c = EQ concentration. d =
slope factor. X = antagonist concentration. EC is the concentra-
tion ofdrug required to displace 50% of['H]s inblastine bindinc.
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Chemosensitization of MDR cell lines by XR9051
The results of experiments using the resistance-modifying agents I
Vpm, CsA and XR905a1 to sensitize a panel of four P-gp-over- E
expressing drug-resistant cell lines to doxorubicin are shown in > i_
Table 1. Two cell lines were of human origin, 2780AD, and 8
H69/LX4, and two cell lines were of murine origin EMT6/AR 1.0 D |/
Johnson and MC26. With the exception of the MC26 line, all cell o 1/j
lines were derived by selection in medium containing doxorubicin. co
MC26 cells represent a model expressing intrinsic resistance to Ir 50_ A ,
cytotoxics. a,
In all cases, co-incubation of cells with doxorubicin and 0.1 IgM - .'
XR9051 resulted in measurable sensitization. At 0.3 tM and 0 ,
0.5 pM, XR9051 was highly active and gave at least a 15- to 20- -X
fold decrease in the doxorubicin IC5,in the acquired resistance cell
lines. This level of sensitization represents full reversal in the
ARI.0 and 2780 AD cells compared with the parental cells and
close to full reversal in the H69/LX4 cells. Similar effects were 001 0.1 1 10
seen in the P388/DX Johnson murine leukaemia cell line (data not Modulator concentration (pM)
shown). In MC26 cells, which express a low level of resistance, a Figure 2 The effect of resistance modulators on the accumulation of [3H]-
six-fold sensitization was observed with 0.5 JIM XR905 1. Across daunorubicin by EMT6/AR 1.0 cells. The ability of XR9051 (A), Vpm (0) and
the panel of cell lines tested, Vpm and CsA were typically 10-fold CsA (E0) to reverse the P-gp-dependent accumulation deficit over a period of
1 h at 370C was carried out as detailed under Materials and methods. and three- to fivefold less potent than XR905 I respectively (Table Results are plotted relative to 100pM Vpm, which restores uptake to levels
1). It is also noteworthy that the higher but submaximal concentra- seen with parental EMT6/P cells. The results shown are representative of at
tions of both Vpm and CsA had inherent cytoxicity in two of four least six independent experiments. Mean ± standard deviation (n= 4)
cell lines in the absence of doxorubicin. No such inherent toxicity
was observed for XR905 1.
In the parental line, EMT6/P, a weak sensitizing influence of and methotrexate. XR9051 (0.3 JM) gave significant reversal of
XR905 1 was noted at 1 JIM, presumably as a result of a basal level MDR in all cases, although the degree ofsensitization by the modu-
of P-gp expression. No effect of XR905 1 on other parental cells lator was dependent on the cytotoxic studied. The residual resis-
was seen. tance factor (Zhou et al, 1997) (IC50 ofcytotoxic in resistant cells in
the presence of 0.3 JM XR9051/IC90 of cytotoxic in parental line)
varied from I (paclitaxel in H69LX4 cells) to 4 (vincristine in
Sensitizing influence of XR9051 on various cytotoxics EMT6 AR1.0 cells) (data not shown). The observation that the effi-
The ability of 0.3 JM XR905 1 to potentiate the antiproliferative cacy of a particular modulator is dependent on the combination of
properties of several clinically relevant cytotoxic agents was exam- cell line and cytotoxic employed is in agreement with several other
ined in the human H69/LX4 and murine EMT6/AR 1.0 cell lines. studies (Hyafil et al, 1993; Dantzig et al, 1996).
(Table 2). Only the activity of agents associated with the MDR
phenotype was sensitized by XR905 1. Thus, the modulator had no Accumulation of [3H]daunorubicin
influence on the activity ofthe non-MDR cytotoxics, 5-fluorouracil The ability of resistance-modifying agents such as XR9051I to
reverse the drug accumulation deficit in P-gp-expressing cell lines
has been widely used to demonstrate inhibition of P-gp-dependent
Table 2 Sensitization of H69/LX4 and EMT6/AR1 .0 cells to cytotoxics by tas andeluae thepotency of com pods.eMurin
0.3 pm XR9051* transport and evaluate the potency of compounds. Murine 0.3 tIM XR9051 v EMT6/AR 1.0 cells were used to determine the efficacy of
Potentiation indexa XR905 1 in reversing the accumulation deficit of [3H]daunorubicin
in MDR cells. As shown in Figure 2, XR9051 had a significant
H69/LX4 EMT6/AR1.0 effect on the accumulation of [3H]daunorubicin at concentrations
Doxorubicin 20, 16 245, 157 below 100 nm. Half-maximal reversal was noted at 0.22 ± 0.06 JIM
Vincristine 600, 400 150,133 (n = 6) and a near-maximal effect was observed at 1 JIM. Half-
Vinblastine 31 maximal reversal of the accumulation deficit by Vpm and CsA
Paclitaxel 140, 143 600, 428 was observed at concentrations of5.8 ± 2.2 JM (n = 18) and 0.44 ±
Etoposide 7, 24 30 0.23 JIM (n = 12) respectively. Little or no enhancement of accu-
Actinomycin D 9, 50
Colchicine 30, 68 mulation was observed with any modulator using the parental
5-Fluorouracil 1.1 EMT6/P cell line (data not shown).
Methotrexate 1.0
Efflux of [3H]daunorubicin
Data points represent potentiation indices from individual experiments.
aPotentiation index is defined as (IC50 of the cytotoxic in the absence of The ability of resistance-modifying agents to inhibit the efflux of
modulator/IC,n of the cytotoxic in the presence of modulator). [3H]daunorubicin from EMT6/AR 1.0 cells was investigated using
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Figure 3 Inhibition of [3H] daunorubicin efflux from EMT6/AR1.0 cells. After
a 'loading phase' of 2 h in the presence of [3H]daunorubicin and 1 gM XR9051
(A) or 1 pM CsA (O), cells were washed and further incubated for the > 0 c 1 2 5 10 20 gM
indicated periods ('efflux phase') in the presence (solid lines) or absencev
(broken lines) of the same modulator. Cell-associated radioactivity was 0 c XR9051 Z (
measured as detailed under Materials and methods. The results shown are =
expressed as the percentage of [3H]daunorubicin remaining in cells, where
100% is the quantity of [3H]daunorubicin in cells at the start of the efflux Figure 5 Inhibition of [3H]azidopine labelling of P-gp by XR9051. Membrane
phase. Data points represent the mean (n= 4) and are representative of at fractions from the H69/P drug-sensitive cell line and the P-gp-overexpressing
least three independent experiments line H69/LX4 were incubated with [3H]azidopine and modulators as detailed
under Materials and methods. After UV-crosslinking, [3H]azidopine binding to
P-gp was visualized by SDS-PAGE followed by autoradiography. The gel
shown is representative of experiments carried out four times
500001
400001 XR905 1). Figure 3 illustrates that, even when excluded from the
EJ EL -0 h efflux medium, XR905 1 remained effective in inhibiting the efflux
Xd _1 h of [3H]daunorubicin from cells, with up to 50% of the initial
. 3 h cellular cytotoxic content remaining at 5 h after removal of
'UM C0000- 1Z 5h XR9051. The loss of 50% is similar to that seen in the parental
.oJ 22 h cells and appears to represent leakage of the radioactive label (data
not shown). The presence of XR9051 in the efflux phase had little
0 20000 or no additional effect on the efflux of [3H]daunorubicin. These
results may indicate that XR905 1 remained active within cells for
CA U) a number of hours after removal from the extracellular medium.
lo 10000 _ ; CsA was able to block efflux from cells when included in the
efflux phase (Figure 3). However, when omitted from the efflux
phase, loss of [3H]daunorubicin from these cells was extremely
0 1 iC rapid, with up to 90% of drug effluxed within the first hour. Thus,
I gmXR9051 10 JMVpm 5gMCsA CsA and Vpm (data not shown) have an extremely short duration
of action, presumably because they are both substrates for export
Figure 4 Inhibition of [3H]daunorubicin accumulation by EMT6/AR1.0 cells
after removal of XR9051 from medium. Cells were exposed to XR9051, Vpm by P-glycoprotein (Boesch and Loor, 1994; Spoelstra et al, 1994).
or CsA for 1 h, washed and incubated in modulator-free medium for the
indicated time points before addition of [3H]daunorubicin and further
incubation for 1 h. Cell-associated radioactivity was measured as detailed Persistence of activity after removal of modulator
under Materials and methods. Time points indicate incubation periods
between removal of modulator and initiating the [3H]daunorubicin The experiment shown in Figure 4 was designed to complement
accumulation assay. Data points represent the mean (±s.d., n = 4), and the data from the previous section that indicates that XR905 1 has a
graph shown is representative of four independent experiments
long duration of action. Cells were exposed to modulator for 1 h
before thorough washing and a further incubation in the absence of
modulator for up to 22 h before assessing the cells ability to accu-
a 'loading phase' of 2 h in the presence of [3H]daunorubicin and mulate [3H]daunorubicin. The results indicate that cells exposed to
modulator, followed by an 'efflux phase' (after washing) in which 1 ,tM XR9051 for 1 h showed complete reversal of the P-gp-
cells were incubated either in daunorubicin and modulator-free dependent accumulation deficit for at least 22 h. The last time
medium or in medium containing modulator only. Resistance point (22 h) showed higher accumulation than the earlier time
modulators were used at a concentration sufficient for maximal points because of cell division taking place during the incubation
reversal of the accumulation deficit (1 ,tM for both CsA and period. The prolonged activity of XR9051 was in sharp contrast to
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Figure 6 Displacem [3 lvnastine bnrig to P-gp in Ch'B30
membranes by XR9051 (0) and Vpm (-). Merrxanes (20 igg) were
incubated with PHIvknblasfine (25-30 rf) and added drug for 120 mirutes
before filtrabon as descried under Materials and metods
Tabile 3 Summary of binding parameters obtained for the displacerrent of
[*inbastine binding in CI+ B30 membranes by XR9051, CsA and Vpm
XR9051 CsA Vpm
Initialbound 1.03 ±0.04 0.96 ± 0.02 1.00± 0.11
Final bound 0.35 ± 0.09 0.04 ± 0.01 0.05 ± 0.13
EC. (nm) 1.40 ± 0.53 4.37 ± 0.80 1270 ± 740
Slope 1.7±0.9 1.2±0.3 0.9±0.6
n 4 3 5
the effects seen after incubation with Vpm (10gM) orCsA (5 gm),
when inhibition of P-gp was almost completely lost 1 h after
removal of the modulator. The concentrations of CsA and Vpm
chosen had demonstrated complete reversal of the accumulation
deficit when coincubated with [3Hldaunorubicin (Figure 2). These
results demonstrate that, in contrast to CsA and Vpm, XR9051 has
a very long duration of action after removal from the incubation
medium.
Inhibition of photoaffinity labelling of P-gp by XR9051
The dihydropyridine azidopine has been widely employed as a
photoaffinity ligand, for both calcium channels and P-gp (Ferry et
al. 1984: Yang et al. 1988). It is possible to evaluate the ability of
resistance-modifying agents to interact directly with P-gp by
examining their inhibition of [3H]azidopine cross-linking to the
170-kDa P-gp band on polyacrylamide gels. Photoaffinity
labelling of cell membranes prepared from H69/LX4 cells
confirmed the presence ofa 170-kDa band that was not present in
membranes prepared from the parental H69/P cell line (Figure 5).
This reflects the pattern of P-gp expression in these cell lines,
which was confirmed by Western blot analysis using the anti-P-gp
antibody C219 (data not shown). As shown in Figure 5, XR9051
(1-20 jM) was able to inhibit the labelling of P-gp by
[3H]azidopine. At 20pM XR9051 gave almost complete abolition
of labelling. CsA at 5 gM was able to inhibit the binding of
azidopine to P-gp.
Inhibition of binding of pHjvinblastine to
P-glycoprotein by XR9051
It has previously been demonstrated that plasma membranes from
CHrB30 cells bind [3H]vinblastine with high affinity as reflected
by a dissociation constant of 36 ± 5 nM (Callaghan et al. 1997).
The density of [3H]vinblastine binding sites in these membranes
was 161 ± 11 pmol mg-'. which translates to P-gp constituting
2.9% of total membrane protein, assuming that 1 mole ofvinblas-
tine binds to 1 mole of P-gp. Non-specific binding to membranes
and filters accounted for 10-15% oftotal binding, and all binding
assays were performed in hypotonic buffer to minimize possible
accumulation ofdrug in the intravesicular space. Membranes from
the parental cell line AuxB 1, which does not express P-gp,
displayed negligible specific binding of the radioligand (data not
shown).
The relative abilities of XR9051 and Vpm to displace the
equilibrium binding of [3H]vinblastine to CHrB30 membranes is
shown in Figure 6, and data obtained using XR9051, Vpm and
CsA are summarized in Table 3.
XR9051 (EC.5 = 1.40 ± 0.53 nM) was significantly more potent
(P < 0.05) than CsA (EC50
= 4.37 ± 0.80 nM) in displacing
[1H]vinblastine binding to P-gp. In contrast. Vpm was approxi-
mately 1000-fold less potent (EC50 = 1270 740 nM). Although
very potent in displacing vinblastine binding, XR9051 (final frac-
tion bound = 0.35) did not completely inhibit the binding of
[3H]vinblastine to P-gp in contrast to CsA and Vpm.
DISCUSSION
This current study was undertaken to characterize a specific
inhibitor of P-gp that is more potent and lacks the side-effects of
some of the modulators currently undergoing clinical assessment
in refractory cancers. Extensive modification of a natural product
lead resulted in XR9051. which was found to be active at
submicromolar concentrations in a number of assays assessing
P-gp-dependent MDR.
Several assays were used to examine the inhibition of P-gp
transport and the direct interaction between XR9051 and its target.
Drug accumulation assays were used to demonstrate that XR9051
reversed the accumulation deficit associated with overexpression
of P-gp. In the murine EMT6/AR 1.0 mammary carcinoma cell
line, XR9051 was more potent than both CsA and Vpm in
restoring [3Hldaunorubicin accumulation. XR9051 also proved
highly potent in reversing the accumulation deficit of the fluores-
cent probes calcein-AM and rhodamine- 123 in human and murine
cell lines (data not shown). In contrast to the resistant cell lines,
XR9051 had little effect on drug accumulation in parental cell
lines, indicating that it exerted its influence through inhibition of
P-gp function. Furthermore, XR9051 showed no activity in a cell
line whose resistance to cytotoxic drugs is mediated by the
multidrug resistance-associated protein, MRP (data not shown).
Thus, XR9051 appears to be a specific inhibitor ofP-gp-mediated
transport. Evidence for a direct interaction between XR9051 and
P-gp was implied by the photoaffmnity labelling studies using the
photoreactive P-gp substrate azidopine. XR9051 appeared to be
less potent than CsA in this assay, which suggests that the two
modulators may not interact with P-gp at exactly the same site.
This interaction was confirmed by the ability of XR9051 to
displace the binding of [3H]vinblastine to P-gp. In this assay
XR9051 was significantly more potent than CsA and Vpm.
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Nevertheless. XR9051 was not able to completely displace
[3H]vinblastine binding. possibly due to an interaction at a region
distinct from the vinblastine binding site as has been proposed for
1.4-dihydropyridines (Ferry et al, 1992). Such a mechanism of
action for XR9051 may explain the discrepancy between the
concentrations needed to displace [3H]vinblastine and those
needed to reverse MDR in cell-based assays. Confirmation ofthis
hypothesis awaits kinetic studies on drug binding.
The characterization of XR9051 was extended to assess the
reversal of the MDR phenotype in a number of cell lines. where
the restoration of cytotoxic drug accumulation in MDR cell lines
was found to correlate with the restoration of cytotoxic-mediated
cell kill. XR9051 was foundto be effective in potentiating the toxi-
city ofseveral clinically relevant MDR drugs in a range ofmurine
and human P-gp-overexpressing MDR cell lines. The cell lines
examined included those of leukaemic origin as well as cell lines
derived from solid tumours such as breast. ovary and lung. A
concentration of 0.3-0.5 gM was sufficient for full reversal of
resistance. In most cases significant potentiation of activity was
seen at concentrations of0.1 JIm. indicating that XR9051 is one of
the more potent modulators known. An important property of an
effective MDR modulator is that its activity persists in vitro for an
extended period following removal from the culture medium. This
feature should give the modulator a significant advantage for clin-
ical administration. Two different transport studies demonstrated
that XR9051 was particularly effective in inhibiting P-gp function
for in excess of 22 h. even after removal from culture medium.
This is in marked contrast to both CsA and Vpm. which are both
known as P-gp substrates. This difference in properties may
suggest that XR9051 is not a substrate for export by P-gp and may
give further evidence that XR9051 binds to a distinct but linked
site to that ofcytotoxics and other P-gp substrates. Nevertheless, it
should be noted that the ability ofaP-gp inhibitor to retain activity
over an extended period may affect the tissue distribution and
pharmacokinetics of other compounds. Studies in mdrla (-I-)
knockout mice have suggested that P-gp can influence the pharma-
cology of drugs other than anti-cancer agents. especially in the
blood-brain barrier (Schinkel et al. 1995).
In summary, XR9051 has been demonstrated to be a potent and
specific inhibitorofP-gp function in vitro. with a superiorduration
of action to other agents tested. The compound is significanfly
more potent than CsA and Vpm. Furthermore. on the basis of
published data. XR9051 is more potent than S9788 (Pierre et al.
1992) and VX71O (Germann et al. 1997). XR9051 is effective in
restoring the sensitivity of many different tumour types to
numerous MDR chemotherapeutic agents and therefore has great
potential in the treatment ofrefractory cancers.
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